Brand Intelligence Graph
Company Overview
About Agomab Therapeutics
Agomab Therapeutics went public on Nasdaq in February 2026, raising approximately $200 million at an ~$780 million valuation (ticker: AGMB), becoming one of the first European biotechs to list in the US in 2026. Agomab is developing ontunisertib — the only clinical-stage gut-restricted ALK5/TGFβR1 inhibitor for fibrostenosing Crohn's disease, a severe complication where intestinal fibrosis causes strictures requiring repeated surgery. The company also has AGMB-447 in Phase 1 for idiopathic pulmonary fibrosis (IPF), using lung-restricted delivery of the same mechanism.
Business Model & Competitive Advantage
Fibrostenosing Crohn's disease affects approximately 30% of Crohn's patients and has zero approved treatments specifically for the fibrotic complication — standard Crohn's therapies address inflammation but not the fibrotic strictures that cause bowel obstruction. Ontunisertib's gut-restricted delivery (not absorbed systemically) targets the fibrotic process directly in intestinal tissue while avoiding the systemic side effects that broad TGFβ inhibition causes.
Competitive Landscape 2025–2026
The dual-indication strategy using lung-restricted versus gut-restricted delivery of the same ALK5 inhibitory mechanism provides clinical efficiency: positive proof-of-concept data in one indication validates the mechanism for the other, and the development infrastructure for both programs is largely shared. Agomab's Nasdaq listing provides capital market access for both development programs simultaneously.
Key Differentiators
Emerging Innovator
Agomab Therapeutics is an emerging player bringing innovative solutions to the BioTech market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Emulate
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the m
ConcertAI
ConcertAI is a Boston-based company that combines artificial intelligence with real-world oncology data to accelerate cancer drug development and improve patient outcomes. Its platform integrates mult
DNAnexus
DNAnexus is the category-defining cloud platform for precision health data management, analysis, and collaboration. Founded in 2009 and headquartered in Mountain View, California, DNAnexus provides a
Saluda Medical
Saluda Medical is a commercial-stage medical device company that has pioneered closed-loop neuromodulation therapy for chronic pain management. Headquartered in Macquarie Park, Australia (with US oper
Tempus
Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder o
Schrödinger
Schrödinger was founded in 1990 by Richard Friesner and David Pearlman in New York City, building physics-based computational methods for molecular simulation. For over 30 years the company has develo
Compare Agomab Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Agomab Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Agomab Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Agomab Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →